الملخص
Type I neurofibromatosis is characterised by altered skin pigmentation and the growth of benign tumours, particularly along the peripheral nerves and central nervous system. We report a 36-year-old primigravida woman in labour who was admitted to the obstetric suite of the Hospital Sant Joan de Déu, Barcelona, Spain, in 2007 with hypothyroidism, type I neurofibromatosis and a factor V Leiden mutation. Due to a lack of cranial and spinal imaging data, an epidural was not indicated; instead, continuous intravenous remifentanil analgaesia was administered. The remifentanil infusion was self-titrated by the patient using a visual analogue scale, with the dosage ranging from 0.01 to 0.25 μg/kg/minute. Due to rotational dystocia, Kjelland-type forceps were used during the delivery. After birth, the infant was found to have Apgar scores of 9 and 10, with no maternal or neonatal adverse effects observed. Although still controversial, remifentanil may be a successful alternative for analgaesia in similar cases; however, the specific risks and benefits for each patient should be considered prior to administration.
بيانات النشر
- المعرّف الرقمي
- 10.18295/squmj.2017.17.04.016
- المجلة
- مجلة جامعة السلطان قابوس الطبية, 17(4), 468-471
- الناشر
- جامعة السلطان قابوس
- وصول مفتوح
- وصول مفتوح ذهبي
- الترخيص
- CC BY-ND 4.0
اقتبس هذه المقالة
APA 7
Gálvez, J. L., Errando, C. L., Martín-Ayuso, S., Marga, & Valverde-Mantecón, J. M. (2025). Intravenous Remifentanil Analgaesia for an Obstetric Patient with Type I Neurofibromatosis and a Factor V Leiden Mutation. Sultan Qaboos University Medical Journal, 17(4), 468-471. https://doi.org/10.18295/squmj.2017.17.04.016
MLA 9
Gálvez, José L., et al. "Intravenous Remifentanil Analgaesia for an Obstetric Patient with Type I Neurofibromatosis and a Factor V Leiden Mutation." Sultan Qaboos University Medical Journal, vol. 17, no. 4, 2025, pp. 468-471. https://doi.org/10.18295/squmj.2017.17.04.016.
شيكاغو (المؤلف–التاريخ)
Gálvez, José L., Carlos L. Errando, Silvia Martín-Ayuso, Marga, and José M. Valverde-Mantecón. 2025. "Intravenous Remifentanil Analgaesia for an Obstetric Patient with Type I Neurofibromatosis and a Factor V Leiden Mutation." Sultan Qaboos University Medical Journal 17 (4): 468-471. https://doi.org/10.18295/squmj.2017.17.04.016.
هارفارد
Gálvez, J. L., Errando, C. L., Martín-Ayuso, S., Marga and Valverde-Mantecón, J. M. (2025) 'Intravenous Remifentanil Analgaesia for an Obstetric Patient with Type I Neurofibromatosis and a Factor V Leiden Mutation', Sultan Qaboos University Medical Journal, 17(4), pp. 468-471. doi:10.18295/squmj.2017.17.04.016.
فانكوفر
Gálvez JL, Errando CL, Martín-Ayuso S, Marga, Valverde-Mantecón JM. Intravenous Remifentanil Analgaesia for an Obstetric Patient with Type I Neurofibromatosis and a Factor V Leiden Mutation. Sultan Qaboos University Medical Journal. 2025;17(4):468-471. doi:10.18295/squmj.2017.17.04.016
IEEE
J. L. Gálvez, C. L. Errando, S. Martín-Ayuso, Marga, and J. M. Valverde-Mantecón, "Intravenous Remifentanil Analgaesia for an Obstetric Patient with Type I Neurofibromatosis and a Factor V Leiden Mutation," Sultan Qaboos University Medical Journal, vol. 17, no. 4, pp. 468-471, 2025, doi: 10.18295/squmj.2017.17.04.016.